BridgeMD
New treatment option for Advanced/Metastatic Breast Cancer
Official title Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
ClinicalTrials.gov ID: NCT07610720
What this study is testing
What is Dalpiciclib?
Dalpiciclib is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for advanced/metastatic breast cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75, women only
You may be able to join if
- Females aged 18 to 75 years with pathologically confirmed metastatic or locally advanced unresectable breast cancer.
- Hormone receptor (HR)-positive and HER2-positive.
- Patients with no evidence of disease progression (including CR, PR, or SD)after 4-8 cycles of first-line systemic anti-tumor therapy.
- ECOG Performance Status: 0-1.
You likely can't join if
- Symptomatic active brain metastases or extensive leptomeningeal metastases.
- History of Grade 3 or 4 allergic reaction related to the study drugs.
- Currently receiving other anti-tumor therapies.
The study team makes the final eligibility decision.
Where it's taking place
- Guangdong, GUANGZHOU, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangdong, GUANGZHOU, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.